Rare Cardiovascular Disease Therapeutics Market

Hypertrophic cardiomyopathy leads the rare cardiovascular disease therapeutics market with a 43.0% share in 2026, followed by gene therapy at 44.5%. Market demand depends on precise genetic diagnosis, specialist referral pathways, and disease-specific treatment development, while long-term safety monitoring and manufacturing scalability remain critical for wider adoption.